Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| GeneDx Holdings Corp.WGS · Entity 1634 | CHIEF TRANSFORMATION OFFICER | March 16, 2024 | March 19, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
GeneDx Holdings Corp.
Report date March 16, 2024 · Filed March 19, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 29,517 |
Ending reported balance
After 2024-03-18 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2024-03-16 · Exercise / conversion · Acquired 5,114 · Balance 31,525 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Row 2 · 2024-03-18 · Sale · Disposed 2,008 · Balance 29,517 F2: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 61,362 |
Reported balance
After 2024-03-16 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-03-16 · Exercise / conversion · Disposed 5,114 · Balance 61,362 F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration.
F2: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction.
F3: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 18, 2024 Filed Mar 19, 2024 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,008 | $10.59 | $21,269.34 |
DisclosureSEC source: 0001415889-24-008502 · form4-03192024_080346.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,517 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.11 to $10.6501 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| March 16, 2024 Filed Mar 19, 2024 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008502 · form4-03192024_080346.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 61,362 Underlying: Class A Common Stock · 5,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 16, 2024 Filed Mar 19, 2024 20:14 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-008502 · form4-03192024_080346.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,525 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| March 12, 2024 Filed Mar 13, 2024 20:22 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 897 | $9.21 | $8,260.92 |
DisclosureSEC source: 0001415889-24-007805 · form4-03132024_080331.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,411 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of restricted stock units. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $9.00 to $9.21, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007681 · form4-03122024_090335.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 31,249 Underlying: Class A Common Stock · 2,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| March 09, 2024 Filed Mar 12, 2024 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-007681 · form4-03122024_090335.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,308 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 22, 2024 Filed Jan 23, 2024 21:10 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 193 | $3.24 | $625.32 |
DisclosureSEC source: 0001415889-24-001671 · form4-01232024_090114.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,467 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:10 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001671 · form4-01232024_090114.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,183 Underlying: Class A Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| January 19, 2024 Filed Jan 23, 2024 21:10 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-001671 · form4-01232024_090114.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · CHIEF TRANSFORMATION OFFICER 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,660 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| January 03, 2024 Filed Jan 4, 2024 22:03 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 105 | $2.58 | $270.89 |
DisclosureSEC source: 0001209191-24-000840 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,114 F1 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.5725 to $2.58, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000376 · doc4.xml · derivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,455 Underlying: Class A Common Stock · 273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| January 01, 2024 Filed Jan 3, 2024 21:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-24-000376 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,219 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 18, 2023 Filed Dec 20, 2023 02:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,700 | $2.16 | $3,670.98 |
DisclosureSEC source: 0001209191-23-059289 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,946 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.90 to $2.49, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 16, 2023 Filed Dec 20, 2023 02:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059289 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 66,476 Underlying: Class A Common Stock · 5,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| December 16, 2023 Filed Dec 20, 2023 02:25 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-059289 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,646 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| December 11, 2023 Filed Dec 12, 2023 21:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 850 | $1.61 | $1,368.84 |
DisclosureSEC source: 0001209191-23-058263 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,532 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $1.57 to $1.665, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| December 09, 2023 Filed Dec 12, 2023 21:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058263 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 34,090 Underlying: Class A Common Stock · 2,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| December 09, 2023 Filed Dec 12, 2023 21:05 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058263 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 21,382 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 20, 2023 Filed Oct 23, 2023 21:52 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 164 | $3.44 | $564.16 |
DisclosureSEC source: 0001209191-23-053359 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,541 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:52 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-053359 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,729 Underlying: Class A Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| October 19, 2023 Filed Oct 23, 2023 21:52 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-053359 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,705 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| October 03, 2023 Filed Oct 3, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 85 | $3.56 | $302.66 |
DisclosureSEC source: 0001209191-23-051462 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,159 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.56 to $3.62, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-051462 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,728 Underlying: Class A Common Stock · 273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| October 01, 2023 Filed Oct 3, 2023 20:19 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-051462 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,244 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 18, 2023 Filed Sep 19, 2023 22:08 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,580 | $4.16 | $6,575.49 |
DisclosureSEC source: 0001209191-23-050053 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,971 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.08 to $4.1649, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 22:08 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-050053 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 71,590 Underlying: Class A Common Stock · 5,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 16, 2023 Filed Sep 19, 2023 22:08 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-050053 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,551 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| September 11, 2023 Filed Sep 12, 2023 22:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 846 | $4.62 | $3,911.90 |
DisclosureSEC source: 0001209191-23-049135 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 14,437 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.48 to $4.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| September 09, 2023 Filed Sep 12, 2023 22:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-049135 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 36,931 Underlying: Class A Common Stock · 2,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| September 09, 2023 Filed Sep 12, 2023 22:41 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-049135 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,283 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 20, 2023 Filed Jul 22, 2023 01:58 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 163 | $7.85 | $1,279.55 |
DisclosureSEC source: 0001209191-23-043166 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,442 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 01:58 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 546 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-043166 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,821 Underlying: Class A Common Stock · 546 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 19, 2022, and thereafter vests as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| July 19, 2023 Filed Jul 22, 2023 01:58 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 546 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-043166 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,605 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| July 03, 2023 Filed Jul 5, 2023 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 83 | $5.99 | $497.17 |
DisclosureSEC source: 0001209191-23-041207 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,059 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 273 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-041207 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 3,001 Underlying: Class A Common Stock · 273 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F3 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| July 01, 2023 Filed Jul 5, 2023 21:16 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 273 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-041207 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,142 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 62 | $6.31 | $391.22 |
DisclosureSEC source: 0001209191-23-038751 · doc4.xml · nonDerivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,869 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. Read SEC document |
| June 20, 2023 Filed Jun 21, 2023 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 1,159 | $6.37 | $7,383.18 |
DisclosureSEC source: 0001209191-23-038751 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,931 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.23 to $6.67, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 5,114 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-038751 · doc4.xml · derivative · entry 4 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,704 Underlying: Class A Common Stock · 5,114 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:04 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 5,114 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-038751 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| June 12, 2023 Filed Jun 13, 2023 21:22 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 845 | $6.49 | $5,483.88 |
DisclosureSEC source: 0001209191-23-036824 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 7,976 F2 · kind: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.10 to $6.77, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth herein. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:22 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 2,841 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-036824 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,772 Underlying: Class A Common Stock · 2,841 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period commencing on March 9, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| June 09, 2023 Filed Jun 13, 2023 21:22 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 2,841 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-036824 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,821 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 26, 2023 Filed Apr 27, 2023 23:40 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | GrantRestricted Stock Unit · Derivative | 2,700,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025920 · doc4.xml · derivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 2,700,000 Underlying: Class A Common Stock · 2,700,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F2 · derivative.exercise_date: 6.25% vest in quarterly installments over the four-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. F2 · derivative.expiration_date: 6.25% vest in quarterly installments over the four-year period commencing on March 16, 2023 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 20, 2023 Filed Apr 21, 2023 20:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 5,338 | $0.31 | $1,658.52 |
DisclosureSEC source: 0001209191-23-025203 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 197,335 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 18,014 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-025203 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 126,102 Underlying: Class A Common Stock · 18,014 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F3 · derivative.exercise_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. F3 · derivative.expiration_date: 3/16th of the total shares vested on October 25, 2021, 1/16th of the total shares vested on January 25, 2022, and thereafter will vest as to 1/16th of the total shares underlying the award in quarterly installments until fully vested on January 19, 2025, subject to the Reporting Person's continued service to the Issuer on each vesting date. Read SEC document |
| April 19, 2023 Filed Apr 21, 2023 20:37 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 18,014 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-025203 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 202,673 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
| April 03, 2023 Filed Apr 4, 2023 23:15 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | SaleClass A Common Stock | 2,776 | $0.34 | $941.34 |
DisclosureSEC source: 0001209191-23-023006 · doc4.xml · nonDerivative · entry 2 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 184,659 F2 · kind: The sales reported on this Form 4 represent shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sales were to satisfy tax withholding obligations to be funded by a "sell to cover" transaction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold as part of a block trade for multiple transactions at prices ranging from $0.3266 to $0.36, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth herein. Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 23:15 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionRestricted Stock Unit · Derivative | 9,005 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-023006 · doc4.xml · derivative · entry 3 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 108,066 Underlying: Class A Common Stock · 9,005 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. F4 · derivative.exercise_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date F4 · derivative.expiration_date: 6.25% vest in quarterly installments over the 4-year period on April 4, 2022 until fully vested, subject to the Reporting Person's continued service to the Issuer on each vesting date Read SEC document |
| April 01, 2023 Filed Apr 4, 2023 23:15 UTC | GeneDx Holdings Corp. WGS · Entity 1634 | Exercise / conversionClass A Common Stock | 9,005 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-023006 · doc4.xml · nonDerivative · entry 1 Saad Kareem · CIK 0001873805 · Chief Transformation Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 187,435 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Class A Common Stock upon settlement for no consideration. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.